A regimen of prophylaxis of thromboembolism with low molecular weight heparin (LMWH) and unfractionated heparin (UFH) in orthopedic surgery is presented. Over a 5-year period, 11,905 patients have been operated in all fields of orthopedic surgery in a big trauma center. In 498 cases, deep vein thrombosis (DVT) was clinically suspected and phlebography was performed: 122 patients had confirmed DVT (rate 0.98%); 59.8% of the DVT were limited to the calf. Nineteen pulmonary embolisms (rate 0.16%) were diagnosed (3 lethal). Heparin-induced thrombocytopenia type II was diagnosed in 12 of 122 patients. Only one of these had received Address correspondence and reprint requests to Dr.
During previous years, several new antithrombotic agents have been developed, such as fondaparinux (1) , hirudin (2) , and melagatran (3) .
Nevertheless, low-molecular-weight heparins (LMWHs) are still standard for prophylaxis of postoperative thromboembolism in orthopedic surgery. Their efficiency especially in high-risk patients has been proven in many clinical trials (4) (5) (6) .
Most of these trials have been carried out in a homogenous patient population after total hip replacement (7, 8) . However no publications about daily practice of thromboembolic prophylaxis with LMWH in general orthopedic surgery could be found. We therefore report on our experience with the LMWH dalteparin in more than 11,000 patients over 5 years.
MATERIALS AND METHODS
Our institution is a big trauma center that is focused on the treatment of patients with multiple injuries (especially with spine and pelvic fractures), reconstructive orthopedic surgery, arthroscopic procedures of all joints, and the therapy of bone and joint infections. Therefore, a great number of patients had a high risk for thromboembolic complications.
In 1995, we changed the regimen of prophylaxis of thromboembolism from unfractionated heparin (UFH) to the LMWH dalteparin, which is available in two dosages: Fragmin®P (2500 IE anti-factor Xa) and Fragmin®P forte (5000 IE anti-factor Xa) (Pharmacia, Erlangen, Germany). Regarding the recommendations of the German Society of Surgery (9) and the European consensus conference (10), we classified the patients into three risk groups (Table 1) . Approximately 40% of the patients had a moderate risk, 60% a high risk, and only a few a highest risk.
Patients with moderate risk received 2,500 IE dalteparin, patients with high risk received 5,000 IE dalteparin once daily subcutaneous. Patients with highest risk received activated partial thromboplastin time (aPPT)-adjusted UFH intravenously for 3 to 7 days before the regimen had been changed to 5,000 IE dalteparin subcutaneously. All patients treated in the intensive care unit also got initially intravenous UFH. In elective orthopedic surgery, prophylaxis started the evening before the operation, in trauma patients who underwent surgery immediately after the operative procedure. Trauma patients who had to undergo surgery with delay received the prophylaxis from the day of trauma according to their risk classification.
Perioperatively the scheme of prophylaxis depended on the kind of anaesthesia, because in spinal anaesthesia there had to be an interval of 12 hours after last application of 2,500 IE dalteparin and 24 hours after 5,000 IE dalteparin ( Table 2) . Prophylaxis was continued until the patients had regained their individual mobility they had had before the trauma or operation.
In all cases, clinically suspected of deep vein thrombosis (DVT), phlebography or, if not possible, duplex sonography was performed. Pulmonary embolism (PE) was diagnosed clinically or with spiral computed tomography or scintigraphy. Patients with proven DVT/PE were investigated for a heparin-induced thrombocytopenia type II (HIT type II) by thrombocyte aggregation assay and enzyme-linked immunosorbent assay (ELISA) (Asserachrom® HPIA, Diagnostica Stago, France) on the day the DVT/PE was diagnosed. The DVT or PE was treated with intravenous UFH.
From July 1, 1995, all thromboembolic events were recorded prospectively over 5 years. During these 5 years 11,905 patients (3,918 women, 7,987 men; mean age 43.2 years [range, 2-99]) underwent surgery in our institution and received prophylaxis for thromboembolism according to the previously mentioned regimen.
Seventy-three received UFH exclusively, and 5 exclusively danaparoid (Orgarans, Thiemann, Waltrop, Germany). All others were given dalteparin (in some cases after an initial period of 3-7 days of intravenous UFH).
RESULTS
DVT was suspected in 498 patients in the lower extremity (49 times bilaterally); therefore, phlebograph was performed. (Table 3) .
Nineteen patients showed clinical signs of PE. In three cases, PE was lethal; in four cases, respirator therapy was necessary. In four patients with PE, a DVT could not be diagnosed. Thus, the overall rate of clinically symptomatic and objectively confirmed DVT was 0.98% (117 of 11,905 patients) and the overall rate of PE was 0.16% (19 of 11,905). One hundred three of the 121 patients with thromboembolic complications received dalteparin for prophylaxis, 15 UFH, and three danaparoid.
The time between trauma/operation and diagnosis of DVT was a median of 9 days (range, 1-42). Furthermore, the diagnosis-related incidence of DVT was determined ( Table 4 ). The number of DVT was significantly highest in tibial head fractures (chi-square test; p<0.01) whereas the DVT were most extensive in patients with multiple injuries.
One hundred five of 121 patients were tested for HIT type II. In 12 of these 105 patients, a HIT type II was found in the laboratory assays. Only one of these patients exclusively received LMWH. All others received UFH for at least 4 days. In four patients who had been given LMWH for prophylaxis, the initial test of HIT type II at the time of diagnosis of the DVT had been negative. With UFH, a progression of the DVT was found. The repeat test of HIT type II showed then a positive result in all four cases. 
DISCUSSION
Several studies have provided evidence that only 5% to 20% of the phlebographically diagnosed DVT were clinically symptomatic (7, 11, 12) . Since in our observation study only clinically symptomatic patients were submitted to phlebography the overall rate of 0.98% DVT cannot reflect the actual number of all DVT. Nevertheless, three fourths of all phlebographies that were performed to diagnose DVT were negative and 50% of the DVTs extended only into parts of the calf veins. So obviously the indication for phlebography was seen at the slightest suspicion and at an early stage of DVT (9 days median).
The great number of distal DVT (more than 55%) backs up the findings of others that the use of LMWH reduces the number of proximal DVT in comparison to UFH (6, 7, 12) . Two aspects seem to be important in this study. The highest rate of DVT was not found after elective orthopedic surgery, such as total hip or knee replacement, but after fractures of the tibial head. The rates of DVT in patients with multiple injuries and after total knee replacement were equal, but the extent of DVT was most serious after multiple injuries. So our results show that the highest risks for DVT are found in trauma patients.
The results of the HIT type II tests were positive in approximately 10% of all patients with DVT. Only one of 12 positive patients had received LMWH exclusively, but after initial negative results, four patients showed a conversion into a positive test result during therapy of DVT with UFH. As reported by Warkentin and associates (13) HIT type II was much rarer with LMWH than with UFH. Considering these findings, therapy of DVT should be performed with LMWH.
The thromboembolic events were more severe in patients with a positive HIT type II test result. So it may be helpful to test all patients with DVT for HIT type II to discontinue heparin as early as possible.
